Equity Details
Price & Market Data
Price: $4.04
Daily Change: -$0.09 / 2.23%
Daily Range: $4.04 - $4.12
Market Cap: $151,146,880
Daily Volume: 2,269
Performance Metrics
1 Week: -4.94%
1 Month: -4.03%
3 Months: -14.77%
6 Months: -14.77%
1 Year: -5.49%
YTD: -7.31%
About Molecular Partners AG (MOLN)
Comprehensive market data and analysis for Molecular Partners AG (MOLN). Current price: 4.04, daily change: -$0.09 / 2.23%. Market cap: 151,146,880. View detailed YTD, 1-week, and 1-month performance.
Company Details
Employees: 149
Sector: Health technology
Industry: Biotechnology
Country: Switzerland
Details
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.